Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a disease that significantly impacts the quality of life (QoL) and physical activities of patients. CRSwNP is an immunologically triggered chronic inflammatory disease of the mucosa and subepithelial tissues for which specific endotype-based immunologic therapies have been developed only in the last decade. So far, no generally accepted recommendations for the diagnosis and therapy of CRSwNP have been developed, nor have criteria been formulated on how to use the currently approved treatment options and biologics. With novel knowledge and treatment options available, there is a growing need to provide advice to physicians and patients on how to define optimum diagnoses, treatment, monitoring, and to use the same nomenclature of disease-related issues. Novel goals of care in CRSwNP need clear definitions and communication across all healthcare professionals (HCPs) dealing with CRS, and to agree on how to measure therapeutic treatment responses and set treatment goals.

To achieve this, the ROC ENT group would like to set up this series of Task Forces.